Safe as mother's milk: Carbohydrates as future anti-adhesion drugs for bacterial diseases

Glycoconjugate Journal

Volumn 17, Issue 7-9, 2000, Pages 659-664

  Sharon, Nathan ^a   Ofek, Itzhak ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Fimbriae; Glycolipids; Glycoproteins; Infection; Lectins; Oligosaccharides

Indexed keywords

ANTIINFECTIVE AGENT; GLYCOPROTEIN; LACTOSE; N ACETYLNEURAMINIC ACID DERIVATIVE; N ACETYLNEURAMINYL(ALPHA 2-3) LACTOSE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BACTERIUM ADHERENCE; BREAST MILK; CARBOHYDRATE ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; HUMAN CELL; HUMAN TISSUE; LECTIN BINDING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANIMALS; BACTERIAL ADHESION; BACTERIAL INFECTIONS; BINDING SITES; CARBOHYDRATE SEQUENCE; CARBOHYDRATES; CHILD, PRESCHOOL; CLINICAL TRIALS; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA;

ANIMALIA; BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE SEROTYPE A; HELICOBACTER PYLORI; HEMOPHILUS; HEMOPHILUS INFLUENZAE; MAMMALIA; ORYCTOLAGUS CUNICULUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034441393     PISSN: 02820080     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011091029973     Document Type: Review

References (24)

1. 1 Ofek I, Doyle RJ, Bacterial adhesion to cells and tissues, (Chapman & Hall, 1994), pp. 1-578.
2. 2 Beuth J, Ko HL, Pulverer G, Uhlenbruck G, Pichlmaier H, Importance of lectins for prevention of bacterial infection and cancer metastases, Glycoconjugate J 12, 1-6 (1995).
3. 3 Zopf D, Roth S, Oligosaccharides as anti-infective agents, Lancet 347, 1017-21 (1996).
4. 4 Kahane I, Ofek I, (eds), Toward anti-adhesion therapy for microbial diseases, Adv Exptl Medicine and Biol 408, 1-288 (1996).
5. 5 Sharon N, Lis H, Microbial lectins and their receptors. In Glycoproteins, edited by Montreuil J, Vliegenthart JFG, Schachter H, Vol. 2 (Elsevier, 1996), pp. 475-506.
6. 6 Karlsson KA, Meaning and therapeutic potential of microbial recognition of host glycoconjugates, Mol Microbiol 29, 1-11 (1998).
7. 7 Roberts JA, Marklund BI, Ilver D, Haslam D, et al., The Galα(1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract, Proc Natl Acad Sci USA 91, 11189-93 (1994).
8. 8 Connell H, Agace W, Klemm P, Schembri M, et al., Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract, Proc Natl Acad Sci USA 93, 9827-32 (1996).
9. 9 Karlsson KA, Abul Milh M, Andersson C, Ångstrom J, et al., Carbohydrate attachment sites for microbes on animal cells: Aspects on the possible use of analogs to treat infections. In Complex Carbohydrates in Drug Research, edited by Bock K, Clausen H, (Munksgaard, Copenhagen, 1994), pp. 396-409.
10. 10 Barthelson R, Mobasseri A, Zopf D, Simon P, Adherence of Streptococcus pneumoniae to respiratory epithelial cells is inhibited by sialylated oligosaccharides, Infect Immun 66, 1439-44 (1998).
11. 11 Idanpään-Heikkilä I, Simon PM, Zopf D, Vullo T, et al., Oligosaccharides interfere with the establishment and progression of experimental pneumococus pneumonia, J Infect Dis 176, 704-12 (1997).
12. 12 Simon PM, Goode PL, Mobasseri A, Zopf D, Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic-acid containing oligosaccharides, Infect Immun 65, 750-7 (1997).
13. 13 Ashkenazi S, A review of the effect of human milk fractions on the adherence of diarrheogenic Escherichia coli to the gut in an animal model, Isr J Med Sci 30, 335-8 (1994).
14. 14 Coppa GV, Pierani P, Zampini L, Carloni I, et al., Oligosaccharides in human milk during different phases of lactation, Acta Paediatr Suppl 88(430), 89-94 (1999).
15. 15 Glaser V, Neose technologies sets the stage for large-scale testing of its anti-ulcer drug, Genetic Engineering News September 1, 1997, pp. 26, 45.
16. 16 Firon N, Ashkenazi S, Mirelman D, Ofek I, et al., Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Esherichia coli to yeast and intestinal epithelial cells, Infect Immun 55, 472-6 (1987).
17. 17 Langermann S, Palaszynski S, Barnhart M, Auguste G, et al., Prevention of mucosal Esherichia coli infection by FimH-adhesin-based systemic vaccination, Science 276, 607-11 (1997).
18. 18 Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, et al., Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands, Nature 403, 669-72 (2000).
19. 19 Aronson M, Medalia O, Schori L, Ofek I, et al., Prevention of colonization of the urinary tract of mice with Esherichia coli by blocking bacterial adherence with methyl a-D-mannopyranoside, J Infect Dis 139, 29-332 (1979).
20. 20 Moricout M, Petit JM, Carias JR, Julien R, Glycoprotein glycans that inhibit adhesion of Esherichia coli mediated by K99 fimbriae: treatment of experimental colibacillosis, Infect Immun 58, 98-106 (1990).
21. 21 Mysore JV, Wigginton T, Simon PM, Zopf D, et al., Treatment of Helicobacter pylori infection in rhesus monkeys using a novel and-adhesion compound, Gastroenterology 117, 1316-25 (1999).
22. 22 Neose Technologies announces results of phase II clinical trial for pediatric ear infections, News Release, December 20, 1999.
23. 23 Roy R, Synthesis and some applications of chemically defined multivalent glycoconjugates, Curr Opin Struct Biol 6, 692-702 (1996).
24. 24 Endo T, Koizumi S, Large-scale production of oligosaccharides using engineered bacteria, Curr Opin Struct Biol 10, 536-41 (2000).